ArticleJournal of contemporary brachytherapy2026
Ruthenium-106 ocular surface brachytherapy for incompletely excised conjunctival melanoma and squamous cell carcinoma.
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To examine the efficacy and safety of ruthenium-106 ( Material and methods: A retrospective analysis of a consecutive cohort of eight patients (four with CM and four with CSCC), treated at the Department of Ophthalmology of the University Hospital of Heraklion, was performed. All patients underwent adjuvant Results: An overall local tumor control rate of 75% was observed during a follow-up period of 18-75 months. In two patients (one CM and one CSCC), orbital exenteration was required due to orbital invasion. Both cases involved neglected and extensive lesions, suggesting possible pre-existing microscopic deeper infiltration. No radiation-related ocular surface toxicity was observed. Conclusions: In line with previous reports, these findings highlight the role of ocular surface brachytherapy in the management of incompletely excised conjunctival malignancies. Ruthenium-106 surface brachytherapy may represent an effective sole adjunctive treatment option for selected cases of CM and CSCC, even when using plaques designed for intra-ocular applications, such as CCB (BEBIG) plaque.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.